Trial Profile

A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Napabucasin (Primary) ; Capecitabine; Cetuximab; Panitumumab
Indications Colorectal cancer
Focus Therapeutic Use
Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma Oncology

Most Recent Events

16 Jun 2021 Time frame for primary endpoint changed from 8 weeks to 24 months.
20 Jan 2020 Status changed from active, no longer recruiting to completed.
30 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Nov 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com